RJA
HTGM

Raymond James & Associates’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Raymond James & Associates’s Portfolio HTGM Stock Details HTGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-109
Closed -$64K – 3752
2018
Q2 		$64K Sell
109
-2
-2% -$1.3K ﹤0.01% 3433
2018
Q1 		$72K Buy
+111
New +$83.3K ﹤0.01% 3298

Other funds holding HTGM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
PWP
Private Wealth Partners Mill Valley, California $1.3B AUM 26.2% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Raymond James & Associates's HTGM Position: Q3 2018 in Review

Raymond James & Associates sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q3 2018, closing a stake of 109 shares — an estimated $64K sold.

Raymond James & Associates first reported a position in HTGM in Q1 2018 and held it in 2 quarters. The position peaked at $72K in Q1 2018. 54 funds tracked by Wall St. Rank hold HTGM as of Q3 2018.

  • Raymond James & Associates reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • Raymond James & Associates sold 109 HTG Molecular Diagnostics, Inc. Common Stock shares in Q3 2018, an estimated $64K.
  • Raymond James & Associates first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q1 2018 and held it in 2 quarters.
  • Raymond James & Associates's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $72K in Q1 2018.
  • 54 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q3 2018.

Based on Raymond James & Associates's 13F filing for Q3 2018, filed 14 Nov 2018.